SporeGen

SporeGen Limited is a UK-based biotechnology company specializing in the development of novel and innovative products, including spore-forming Bacillus, probiotics, medical foods, and pharmaceuticals. SporeGen has also developed novel preventive and therapeutic products, including vaccines. SporeGen was the first company to use spores as a vaccine delivery vehicle and coordinated Phase 1 studies of mucosal vaccines. The company has several pipeline products, including two unique prevention and treatment methods for Clostridioides difficile infections, and a spore-based preventive agent for COVID-19 and influenza (SPOR-COV®). The company has licensed (and patented) a range of novel interventions and innovative Bacillus technologies to global food and biotechnology companies, leading to many commercial products on the market, including novel probiotic strains HU58® and HU36®.